Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 12/20 | 0.48 |
| ▸ | CYP21A2 | P08686 | 11/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 6/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250743 | 0.89 | CHEK1 (0.47) | CYP17A1CYP21A2CYP11B1CHEK1HTR6 | |
| SCHEMBL5252277 | 0.85 | HTR6 (0.43) | CYP17A1CYP21A2CYP11B1CHEK1HTR6 | |
| SCHEMBL5247480 | 0.84 | CHEK1 (0.43) | CYP17A1CYP21A2CYP11B1CHEK1HTR6 | |
| SCHEMBL5251088 | 0.82 | CHEK1 (0.44) | CYP17A1CYP21A2CYP11B1CHEK1HTR6 | |
| SCHEMBL5250016 | 0.82 | CHEK1 (0.47) | CYP17A1CYP21A2CYP11B1CHEK1HTR6 | |
| SCHEMBL5248603 | 0.81 | CHEK1 (0.48) | CYP17A1CYP11B1CHEK1HTR6CYP3A4 | |
| SCHEMBL5248459 | 0.81 | CHEK1 (0.45) | CYP17A1CYP21A2CYP11B1CHEK1HTR6 | |
| SCHEMBL5250377 | 0.81 | CHEK1 (0.45) | CHEK1HTR6CDK1CDK4CCNA2 | |
| SCHEMBL5254385 | 0.81 | CHEK1 (0.46) | CHEK1HTR6CDK1CDK4CCNA2 | |
| SCHEMBL5254641 | 0.80 | CYP1A2 (0.41) | CYP17A1CHEK1HTR6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1614683-B1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMA (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1218348-B1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2007-10-24 | — | — | EP | disclosed |
| US-7141587-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1614683-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050124662-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS. INC. | 2005-06-09 | — | — | US | disclosed |
| US-6884890-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20040220248-A1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | KANIA ROBERT STEVEN (US) | 2004-11-04 | — | — | US | disclosed |
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, LLC | 2004-09-02 | — | — | US | disclosed |
| US-6534524-B1 | Antiproliferative agents, including axitinib | AGOURON PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6531491-B1 | Methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, | AGOURON PHARAMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, ROCK1 | CYP17A1 1589/4885CYP21A2 2165/4885CYP11B1 769/4885 |
| US-20050124662-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, ROCK1 | CYP17A1 1589/4885CYP21A2 2165/4885CYP11B1 769/4885 |
| US-20040220248-A1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | CDK3, BRAF, ROCK1 | CYP17A1 1589/4885CYP21A2 2165/4885CYP11B1 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.